Last updated: 2026-09-10 02:20:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
InspireMD, Inc. (NSPR) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $0.82, with a market capitalization of $39.96M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.63 to $2.57. This page covers its latest market performance, valuation, price trends and company information.
$39.96M | |
$0.86 | |
$24,937,500.00 | |
$0.63 | |
$0.83 | |
48.62K | |
92.84K | |
-- | |
$2.57 | |
$0.63 | |
-- | |
-- |
InspireMD, Inc. (NSPR) last closed at $0.83 as of 2026-09-09 23:31:00, unchanged from the previous close of $0.83.
During the latest regular trading session, NSPR traded between $0.63 and $24,937,500.00, with a volume of 48.62K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, InspireMD, Inc. (NSPR) moved from $0.85 to $0.82, representing a decline of 3.88% ($0.03).
The stock traded between $0.77 and $0.93 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 55.81 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 9.7%
NSPR is currently trading at $0.82, placing it 9.7% of the way from its 52-week low of $0.63 to its 52-week high of $2.57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 127 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of InspireMD, Inc. (NSPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.